Monopar Therapeutics Inc. Files Amendment No. 1 to 2025 Annual Report: Key Developments For Investors

Overview

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company based in Wilmette, Illinois, has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment was submitted to the SEC on March 27, 2026, and corrects a typographical error in the date of the Report of Independent Registered Public Accounting Firm. The audit report date was changed from “March 27, 2025” to “March 27, 2026”. The amendment also updates certifications from the CEO and CFO as required by Sarbanes-Oxley Act Sections 302 and 906.

Key Points for Investors

• Typographical Correction: The amendment corrects the audit report date. While this is not operationally material, it ensures compliance and accuracy in SEC filings.
• Financial Position: Monopar remains a non-accelerated filer and a smaller reporting company, indicating it is not a large, well-known seasoned issuer. The company is listed on the Nasdaq Capital Market under the ticker symbol MNPR.
• Shares Outstanding: As of March 17, 2026, Monopar reported 6,692,140 shares of common stock issued and outstanding, following a 1-for-5 reverse stock split that became effective on August 12, 2024.
• Liquidity and Going Concern:
  • Monopar states it has sufficient capital to fund operations through December 31, 2027. However, continued funding and progress depend on executing its business strategy, securing additional capital, and/or collaborative research agreements.
  • The company’s ability to advance its core programs—especially ALXN1840 (for Wilson disease) and its radiopharmaceutical pipeline—depends on future financing and partnerships.
  • Management warns that failure to secure future funding or partnerships may materially and adversely affect its business, financial condition, and results of operations.
• Critical Audit Matter: The auditor highlighted the classification of pre-funded warrants as a critical audit matter, requiring complex judgments. This matter relates to the accounting treatment of securities issued in recent financings.
• Financial Performance:
  • Net Loss: Monopar reported a net loss of \$(15,586,419) in 2025 and \$(13,716,894) in 2024.
  • Cash and Investments: As of year-end 2025, the company had cash, cash equivalents, and investments totaling over \$60 million.
  • Stock-Based Compensation: In 2025, the company recorded over \$1.14 million in stock-based compensation expenses.
  • Public Offerings & Financings: Monopar raised significant capital through public offerings and concurrent private placement of pre-funded warrants, net of commissions and fees.
  • Stock Repurchase: The company repurchased common stock, with a total value of \$(34,999,957) in 2025.
  • Reverse Stock Split: All per-share and share amount data reflect a 1-for-5 reverse split as of August 2024.
• Shell Company Status: Monopar confirms it is NOT a shell company, which is important for listing compliance and investor confidence.

Potential Price Sensitive Information

• Going Concern Risk: Although Monopar currently has sufficient cash to fund operations for almost two years, its future is dependent on additional financing and successful execution of its business development strategy. Any failure to secure funding or partnerships could impact share value.
• Reverse Stock Split: The reverse split may affect liquidity and trading dynamics for MNPR shares.
• Significant Financing Activities: Extensive capital raising through public offerings and warrant placements, as well as stock repurchases, could impact existing shareholders—dilution risk, changes in capital structure, and possible volatility.
• Critical Audit Matter: The classification of pre-funded warrants may affect how investors perceive Monopar’s financial reporting and risk profile.

Other Notable Details

• Monopar’s financial statements and supplementary data are included in the amendment, spanning pages F-1 to F-23.
• Monopar’s business strategy focuses on developing ALXN1840 for Wilson disease and advancing novel radiopharmaceuticals.
• Portions of Monopar’s 2026 proxy statement are incorporated by reference into Part III.
• Confidential information is omitted from certain exhibits and filed separately with the SEC.

Conclusion

Investors should be aware of Monopar’s ongoing need for additional funding and the risks associated with clinical-stage biopharmaceutical development. While the amendment itself is primarily administrative, the company’s disclosures around liquidity, going concern, capital raising, and reverse stock split are material and could affect future share price movements. The highlighted critical audit matter and the company’s financial health are of particular importance to shareholders and potential investors.

Disclaimer: This summary is not investment advice. It is based on Monopar Therapeutics Inc.’s SEC filings and public disclosures. Investors should review SEC filings directly and consult professional advisers before making any investment decisions. The information presented may be subject to change and does not guarantee any future performance or outcomes.

View Monopar Therapeutics Historical chart here